Gilead CEO Daniel O'Day (Photo by Paras Griffin/Getty Images for ESSENCE)

Gilead­'s M&A ap­petite is for deals in the 'mid-sin­gle-dig­it bil­lions,' CEO says

Gilead CEO Daniel O’Day says the com­pa­ny will like­ly look for more deals like its $4.3 bil­lion pur­chase of CymaBay Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.